Relapse-associated Worsening and Progression-independent Relapse Activity in Ozanimod-treated Participants with Relapsing Multiple Sclerosis from the RADIANCE and DAYBREAK Trials (P6-6.014)

Massimo Filippi; Jon Riolo; Jeffrey A. Cohen; Hans‐Peter Hartung; Xavier Montalbán; Sven G. Meuth; Léorah Freeman; Tanuja Chitnis; Cristina Granziera; Erik DeBoer; Chun-Yen Cheng; Jennifer Reardon; Chahin Pachaï; James K. Sheffield; Bruce Cree; Ludwig Kappos

doi:10.1212/wnl.0000000000204935

Shared by

Massimo Filippi

Relapse-associated Worsening and Progression-independent Relapse Activity in Ozanimod-treated Participants with Relapsing Multiple Sclerosis from the RADIANCE and DAYBREAK Trials (P6-6.014)

Article 2024 en

Authors

Massimo Filippi
JR
Jon Riolo
JC
Jeffrey A. Cohen

Abstract

1 min read

To determine the incidence and predictors of relapse-associated worsening (RAW) and progression independent of relapse activity (PIRA) in participants treated with ozanimod.

Discussion(0)

No comments yet. Be the first to comment.

Relapse-associated Worsening and Progression-independent Relapse Activity in Ozanimod-treated Participants with Relapsing Multiple Sclerosis from the RADIANCE and DAYBREAK Trials (P6-6.014)

Abstract

Discussion(0)

Related publications

Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study

Use of a Machine Learning Model to Predict Disability Progression in Patients with Relapsing Multiple Sclerosis Treated with Ozanimod (P6-6.006)

Using the Progression Independent of Relapse Activity Framework to Unveil the Pathobiological Foundations of Multiple Sclerosis

Multiple Sclerosis Progression and Relapse Activity in Children

Updated Study Data for Ozanimod in Relapsing Multiple Sclerosis

Related publications

Article2022
Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study
Article2022

Article2024
Use of a Machine Learning Model to Predict Disability Progression in Patients with Relapsing Multiple Sclerosis Treated with Ozanimod (P6-6.006)
Article2024

Article2024
Using the Progression Independent of Relapse Activity Framework to Unveil the Pathobiological Foundations of Multiple Sclerosis
Article2024

Article2023
Multiple Sclerosis Progression and Relapse Activity in Children
Article2023

Article2024
Updated Study Data for Ozanimod in Relapsing Multiple Sclerosis
Article2024